Idiopathisches Parkinson-Syndrom und andere Basalganglienerkrankungen

  • W. H. Oertel
  • D. Brandstädter
  • K. Eggert

Zusammenfassung

Die Basalganglien umfassen das Striatum (Nucleus caudatus, Putamen), den Globus pallidus, die Substantia nigra und den Nucleus subthalamicus. Die Dopamindefiziterkrankung Morbus Parkinson (idiopathisches Parkinson-Syndrom, IPS) geht mit einer Degeneration der dopaminergen Substantia nigra pars compacta einher (Flaherty u. Graybiel 1994). Das IPS ist die häufigste Basalganglienerkrankung mit mehr therapeutischen Optionen als für jede andere Basalganglienstörung. Entsprechend befasst sich das Kapitel vornehmlich mit der symptomatischen Pharmakotherapie und der funktionell-neurochirurgischen Behandlung des IPS. Weitere besprochene Erkrankungen sind die Multisystematrophie, die progressive supranukleäre Blickparese, die Demenz vom Lewy-Körper-Typ, die Chorea Huntington, Dystonien, der essentielle Tremor sowie andere Tremorformen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bain P, Findley LJ, Thompson D, Gresty MA, Rothwell JC, Harding AE, Marsden CD (1994) A study of hereditary essential tremor. Brain 117: 805–824PubMedGoogle Scholar
  2. Biggins CA, Boyd JL, Harrop FM, Madely P, Mindham RHS, Randall JI, Spokes EGS (1992) A controlled longitudinal study of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 55: 566–571PubMedGoogle Scholar
  3. Bormann J (1989) Memantine is a potent blocker of N-methyl-D-asparate (NMDA) receptor channels. Eur J Pharmacol 166: 591–592CrossRefPubMedGoogle Scholar
  4. Brandstädter D, Wächter T, Ulm G, Oertel WH (2002) Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson’s disease. Neurology (Letter) 58: 160–161PubMedGoogle Scholar
  5. Burke RE, Fahn S, Marsden CD (1986) Torsion dystonia: A double blind, prospective trial of high-dosage trihexyphenidyl. Neurology 36: 160–164PubMedGoogle Scholar
  6. Burn DJ, McKeith IG (2003) Current treatment of dementia with Lewy bodies and dementia associated with Parkinson’s disease. Mov Disord 18(Suppl 6): S72–79PubMedGoogle Scholar
  7. Carter JH, Nutt JG, Woodward WR, Hatcher LF, Trotman TL (1989) Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson’s disease. Neurology 39: 552–556PubMedGoogle Scholar
  8. Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ (1997) Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease. J Neurol Neurosurg Psychiatry 63: 228–234PubMedGoogle Scholar
  9. Dengler R, Ceballos-Baumann AO, Konstanzer A (1990) Lokale Therapie mit Botulinum Toxin A bei fokalen Dystonien. Aktuelle Neurol 17: 133–138Google Scholar
  10. Deuschl G (1992) Tremor-Syndrome In: Hopf HC, Poeck K, Schliack H (Hrsg) Neurologie in Praxis und Klinik, Bd. II. Thieme, StuttgartGoogle Scholar
  11. Dingemanse J (2000) Issues important for rational COMT inhibition. Neurology 55(11 Suppl 4): S24–27PubMedGoogle Scholar
  12. Eichhorn T, Oertel W (2001) Macrogol 3350/electrolyte improves constipation in Parkinson’s disease and multiple-system-atrophy. Mov Disord 26: 2276–1177Google Scholar
  13. Findley LJ, Büttner U (1996) Tremor. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (eds) Neurological disorders: course and treatment. Academic Press, San Diego, Pp 853–860Google Scholar
  14. Flaherty AW, Graybiel AM (1994) Anatomy of the basal ganglia. In: Marsden CD, Fahn S (eds) Movement Disorders 3. Butterworth Heinemann, London, Pp 3–27Google Scholar
  15. Freund HJ, Reiners KH, Hömberg V (1985) Differentialdiagnose und Therapie des Tremors. In: Schimrigk K, Haaß A (Hrsg) Zentrale Bewegungsstörungen, Arzneimittelinterferenzen. Perimed, Erlangen, S 109–117Google Scholar
  16. Gasser T (2003) Overview of the genetics of parkinsonism. Adv Neurol 91: 143–153PubMedGoogle Scholar
  17. Gasser T, Harding AE (1996) Huntington’s disease and Sydenham’s chorea. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (eds) Neurological disorders: course and treatment. Academic Press, San Diego, Pp 797–802Google Scholar
  18. Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ et al. (1998) Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 74: 189–192PubMedGoogle Scholar
  19. Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72: 917–933Google Scholar
  20. Ing TS, Dangirdas JT, Soung LS et al. (1979) Toxic effects of amantadine in patients with renal failure. Canad Med Assoc J 120: 695–698PubMedGoogle Scholar
  21. Jankovic J, Schwartz KS (1993) Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 43: 834–836PubMedGoogle Scholar
  22. Jellinger K (1986) Pathology of parkinsonism. In: Fahn S, Marsden CD, Jenner P, Teychenne P (eds) Recent developments in Parkinson’s disease. Raven, New York, Pp 33–66Google Scholar
  23. Jenner P (1994) Oxidative damage in neurodegenerative disease. Lancet 344: 796–798CrossRefPubMedGoogle Scholar
  24. Koller WC, Royse VL (1986) Efficacy of primidone in essential tremor. Neurology 36: 121–124PubMedGoogle Scholar
  25. Lang AE, Lozano AM, Montgomery E, Duff J, Tasker R, Hutchinson W (1997) Posteroventral medial pallidotomy in advanced Parkinson’s disease. N Engl J Med 337: 1036–1042CrossRefPubMedGoogle Scholar
  26. Lees AJ (1987) The Steele-Richardson-Olszewski-Syndrom (progressive supranuclear palsy) In: Marsden CD, Fahn S (eds) Movement disorders 2. Butterworth, London, Pp 272–287Google Scholar
  27. Lieberman A, Estey E, Gopinathan G (1978) Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson’s disease. Neurology (Minneap) 28: 964–968PubMedGoogle Scholar
  28. Limousin P, Krack P, Pollack P, Benazzouz A, Ardouin C, Hoffmann D et al. (1998) Electrical stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 339: 1105–1111CrossRefPubMedGoogle Scholar
  29. Maral Mouradian M (2002) Recent advances in the genetics and pathogenesis of Parkinson’s disease. Neurology 58: 179–185PubMedGoogle Scholar
  30. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubios B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos Machado J, O’Brien J, Playfer J, Reid W (2004) Dementia with Lewy bodies. Lancet Neurol 3(1): 19–28PubMedGoogle Scholar
  31. Marsden CD (1994) Parkinson’s disease. J Neurol Neurosurg Psychiatry 57: 672–681PubMedGoogle Scholar
  32. Oertel WH (1996) Multisystematrophie. In: Conrad B, Ceballos-Baumann, AO (Hrsg) Bewegungsstörungen in der Neurologie. Thieme, Stuttgart, S 69–77Google Scholar
  33. Oertel WH (1996) Progressive supranukleäre Blickparese. In: Conrad B, Ceballos-Baumann, AO (Hrsg) Bewegungsstörungen in der Neurologie. Thieme, Stuttgart, S 78–84Google Scholar
  34. Oertel WH, Deuschl G, Gasser T, Eggert K, Arnold G, Baas H, Przuntek H, Reichmann H, Riederer H, Spieker S, Trenkwalder C (2003) Guidelines for parkinsonian syndromes in Germany 2003. In: Diener HC (ed) Leitlinien für Diagnostik und Therapie in der Neurologie, 2. Aufl. Thieme, Stuttgart, S 38–57Google Scholar
  35. Oertel WH, Fahn (2003) Parkinsonism. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (eds) Neurological disorders: course and treatment, 2nd edn. Academic Press, San Diego, Pp 1021–1079Google Scholar
  36. Palace J, Chandiramani VA, Fowler CJ (1997) Value of sphincter electromyography in the diagnosis of multiple system atrophy. Muscle Nerve 20: 1396–1403CrossRefPubMedGoogle Scholar
  37. Parkenberg H, Pedersen B (1985) Medical treatment of dystonia. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia. Research and treatment (Suppl II, Psychopharmakology). Springer, Berlin Heidelberg New York Tokyo, Pp 111–116Google Scholar
  38. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328/3: 176–183Google Scholar
  39. Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann Neurol 39: 37–45Google Scholar
  40. Quinn N (1994) Multiple system atrophy. In: Marsden CD, Fahn S (eds) Movement disorders 3. Butterworth Heinemann, London, pp 262–281Google Scholar
  41. Ransmayr G, Wenning GK, Seppi K, Jellinger K, Poewe W (2000) Demenz mit Lewy-Körperchen. Nervenarzt 71: 929–935CrossRefPubMedGoogle Scholar
  42. Rascol O, Brooks DJ, Korzyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342: 1484–1491CrossRefPubMedGoogle Scholar
  43. Report of the Therapeutic and Technology Assessment Subcomittee of the American Academy of Neurology (1990) Assessment: the clinical usefulness of botulinum toxin-A in treating neurologic disorders. Neurology 40: 1332–1336Google Scholar
  44. Rijk MC de, Tzourio C, Breteler MMB et al. (EUROPARKINSON Study Group) (1997) Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON collaborative study. J Neurol Neurosurg Psychiatry 62: 10–15PubMedGoogle Scholar
  45. Robbins TW, James M, Lange KW, Owen AM, Quinn NP, Marsden CD (1992) Cognitive performance in multiple system atrophy. Brain 115: 271–291PubMedGoogle Scholar
  46. Schapira AH (1994) Evidence for a mitochondrial dysfunction in Parkinson’s disease — a critical appraisal. Mov Disord 9: 125–138CrossRefPubMedGoogle Scholar
  47. Schwarz J, Tatsch L, Arnold G, Gasser T, Trenkwalder C, Kirsch CM, Oertel WH (1992) 123I-iodobenzamide SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 42: 556–561PubMedGoogle Scholar
  48. Schwarz J, Weis S, Kraft E, Tatsch K, Bandmann O, Mehraein P, Vogl T, Oertel WH (1996) Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy. J Neurol Neurosurg Psychiatry 60: 98–101PubMedGoogle Scholar
  49. Schwarz J, Kornhuber M, Bischoff C, Straube A (1997) Electromyography of the external anal sphincter in patients with Parkinson’s disease and multiple system atrophy: frequency of abnormal spontaneous activity and polyphasic motor unit potentials. Muscle Nerve 20: 1167–1172PubMedGoogle Scholar
  50. Snyder SH, D’Amato RJ (1986) MPTP: A neurotoxin relevant to the pathophysiology of Parkinson’s disease. The 1985 George C Cotzias lecture. Neurology 36: 250–258PubMedGoogle Scholar
  51. Steiger MJ, Quinn NP, Marsden CD (1992) The clinical use of apomorphin in Parkinson’s disease. J Neurol 239/8: 389–393Google Scholar
  52. Stern MB, Braffman BH, Skolnick BE, Hurtig HI, Grossman RI (1989) Magnetic resonance imaging in Parkinson’s disease and parkinsonian syndromes. Neurology 39: 1524–1526PubMedGoogle Scholar
  53. Syndulko K, Gilden ER, Hansch EC, Potvin AR, Tourtelotte WW, Potvin JH (1981) Decreased verbal memory associated with anticholinergic treatment in Parkinson’s Disease patients. Intern J Neuroscience 14: 61–66Google Scholar
  54. Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245: 519–522PubMedGoogle Scholar
  55. Turkka J, Suominen K, Tolonen U, Sotaniemi K, Myllylä VV (1997) Selegiline diminishes cardiovascular autonomic responses in Parkinson’s disease. Neurology 48: 662–667PubMedGoogle Scholar
  56. Volkmann J, Allert N, Voges J, Weiss PH, Freund HJ, Sturm V (2001) Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced Parkinson’s disease. Neurology 56: 548–551PubMedGoogle Scholar
  57. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP (1994) Clinical features and history of multiple system atrophy. Brain 117: 835–845PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2005

Authors and Affiliations

  • W. H. Oertel
  • D. Brandstädter
  • K. Eggert

There are no affiliations available

Personalised recommendations